SG10201710528WA - Treatment of brain cancer with oncolytic adenovirus - Google Patents
Treatment of brain cancer with oncolytic adenovirusInfo
- Publication number
- SG10201710528WA SG10201710528WA SG10201710528WA SG10201710528WA SG10201710528WA SG 10201710528W A SG10201710528W A SG 10201710528WA SG 10201710528W A SG10201710528W A SG 10201710528WA SG 10201710528W A SG10201710528W A SG 10201710528WA SG 10201710528W A SG10201710528W A SG 10201710528WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- brain cancer
- oncolytic adenovirus
- oncolytic
- adenovirus
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
- 230000000174 oncolytic effect Effects 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836230P | 2013-06-18 | 2013-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201710528WA true SG10201710528WA (en) | 2018-01-30 |
Family
ID=51134434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510430RA SG11201510430RA (en) | 2013-06-18 | 2014-06-13 | Treatment of brain cancer with oncolytic adenovirus |
| SG10201710528WA SG10201710528WA (en) | 2013-06-18 | 2014-06-13 | Treatment of brain cancer with oncolytic adenovirus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510430RA SG11201510430RA (en) | 2013-06-18 | 2014-06-13 | Treatment of brain cancer with oncolytic adenovirus |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20160143967A1 (zh) |
| EP (1) | EP3010519B1 (zh) |
| JP (2) | JP6613231B2 (zh) |
| KR (1) | KR20160054456A (zh) |
| CN (1) | CN105722518A (zh) |
| AU (1) | AU2014281826B2 (zh) |
| CA (1) | CA2915973A1 (zh) |
| DK (1) | DK3010519T3 (zh) |
| ES (1) | ES2878549T3 (zh) |
| HK (2) | HK1223823A1 (zh) |
| IL (1) | IL243215B (zh) |
| PL (1) | PL3010519T3 (zh) |
| PT (1) | PT3010519T (zh) |
| RU (1) | RU2689553C2 (zh) |
| SG (2) | SG11201510430RA (zh) |
| WO (1) | WO2014204814A1 (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201604654RA (en) | 2012-01-25 | 2016-07-28 | Dnatrix Inc | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| CA2863523A1 (en) | 2012-02-02 | 2013-08-08 | Juan FUEYO-MARGARETO | Recombinant adenovirus expressing cancer antigens |
| WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| CN110072550A (zh) * | 2016-11-01 | 2019-07-30 | 德那翠丝有限公司 | 用于治疗脑癌的组合疗法 |
| CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
| US20180169271A1 (en) | 2016-12-21 | 2018-06-21 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| US11413280B2 (en) * | 2017-05-19 | 2022-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension |
| WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3669893A1 (en) * | 2018-12-20 | 2020-06-24 | Universidad Autónoma de Madrid | Treatment of p53 mutated/modified cancer-forms with parvovirus |
| AU2020325825A1 (en) | 2019-08-05 | 2022-03-17 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| US20230293590A1 (en) | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| RU2759405C1 (ru) * | 2021-02-26 | 2021-11-12 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ адъювантной адаптивной стереотаксической лучевой терапии в лечении первичных злокачественных глиальных опухолей головного мозга |
| WO2022232176A1 (en) * | 2021-04-26 | 2022-11-03 | Dnatrix, Inc. | Use of oncolytic adenovirus for the treatment of pediatric brain cancer |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| EP0804076A4 (en) | 1994-10-19 | 1998-10-21 | Genetic Therapy Inc | GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES |
| DE69636120T2 (de) * | 1995-11-30 | 2006-11-30 | The Board of Regents, The University of Texas System, Austin | Verfahren und zusammensetzungen zur behandlung von krebs |
| WO2000067576A1 (en) | 1999-05-12 | 2000-11-16 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
-
2014
- 2014-06-13 DK DK14736238.8T patent/DK3010519T3/da active
- 2014-06-13 AU AU2014281826A patent/AU2014281826B2/en not_active Ceased
- 2014-06-13 PT PT147362388T patent/PT3010519T/pt unknown
- 2014-06-13 ES ES14736238T patent/ES2878549T3/es active Active
- 2014-06-13 US US14/899,360 patent/US20160143967A1/en not_active Abandoned
- 2014-06-13 EP EP14736238.8A patent/EP3010519B1/en active Active
- 2014-06-13 CA CA2915973A patent/CA2915973A1/en not_active Abandoned
- 2014-06-13 WO PCT/US2014/042375 patent/WO2014204814A1/en active Application Filing
- 2014-06-13 SG SG11201510430RA patent/SG11201510430RA/en unknown
- 2014-06-13 JP JP2016521479A patent/JP6613231B2/ja active Active
- 2014-06-13 SG SG10201710528WA patent/SG10201710528WA/en unknown
- 2014-06-13 RU RU2016101057A patent/RU2689553C2/ru not_active IP Right Cessation
- 2014-06-13 PL PL14736238T patent/PL3010519T3/pl unknown
- 2014-06-13 KR KR1020167001256A patent/KR20160054456A/ko not_active IP Right Cessation
- 2014-06-13 CN CN201480045528.9A patent/CN105722518A/zh active Pending
-
2015
- 2015-12-17 IL IL24321515A patent/IL243215B/en active IP Right Grant
-
2016
- 2016-10-14 HK HK16111923.1A patent/HK1223823A1/zh unknown
- 2016-12-15 HK HK16114263A patent/HK1225962A1/zh unknown
-
2019
- 2019-11-01 JP JP2019199677A patent/JP6956159B2/ja active Active
-
2021
- 2021-03-05 US US17/193,511 patent/US20210213079A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014281826B2 (en) | 2019-10-17 |
| IL243215B (en) | 2019-10-31 |
| CA2915973A1 (en) | 2014-12-24 |
| RU2016101057A3 (zh) | 2018-03-19 |
| HK1223823A1 (zh) | 2017-08-11 |
| IL243215A0 (en) | 2016-02-29 |
| CN105722518A (zh) | 2016-06-29 |
| US20160143967A1 (en) | 2016-05-26 |
| AU2014281826A1 (en) | 2016-01-21 |
| RU2016101057A (ru) | 2017-07-21 |
| KR20160054456A (ko) | 2016-05-16 |
| ES2878549T3 (es) | 2021-11-19 |
| JP6613231B2 (ja) | 2019-11-27 |
| HK1225962A1 (zh) | 2017-09-22 |
| US20210213079A1 (en) | 2021-07-15 |
| PL3010519T3 (pl) | 2021-09-27 |
| JP2016523861A (ja) | 2016-08-12 |
| EP3010519A1 (en) | 2016-04-27 |
| EP3010519B1 (en) | 2021-04-07 |
| RU2689553C2 (ru) | 2019-05-28 |
| WO2014204814A1 (en) | 2014-12-24 |
| JP6956159B2 (ja) | 2021-10-27 |
| PT3010519T (pt) | 2021-07-02 |
| SG11201510430RA (en) | 2016-01-28 |
| DK3010519T3 (en) | 2021-05-17 |
| JP2020033373A (ja) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225962A1 (zh) | 使用溶瘤腺病毒的腦癌治療 | |
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| HK1219231A1 (zh) | 治療兒童實體瘤的方法 | |
| HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| HK1213817A1 (zh) | 治療癌症的方法 | |
| HK1219513A1 (zh) | 治療癌症的方法 | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| GB201607581D0 (en) | Treatment of cancer | |
| HK1232118A1 (zh) | 癌症的治療 | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP3007712A4 (en) | Treatment of cancer | |
| GB201518731D0 (en) | Tumour Therapy | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201300546D0 (en) | Cancer Treatment | |
| SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer | |
| GB201308365D0 (en) | Tumour therapy |